STOCK TITAN

Vir Biotechnology (VIR) director receives 8,000 RSUs and 16,000 stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Vir Biotechnology, Inc. director Jeffrey S. Hatfield reported receiving new equity compensation. He acquired 8,000 restricted stock units (RSUs) under the company’s Equity Incentive Plan, which will vest in full on May 27, 2027. He also received a stock option for 16,000 shares of common stock at an exercise price of $9.10 per share, vesting and becoming exercisable in full on May 27, 2027 and expiring on May 26, 2036. Following the RSU grant, he holds 39,806 shares of common stock directly. These awards are compensation-related grants rather than open-market purchases or sales.

Positive

  • None.

Negative

  • None.
Insider Hatfield Jeffrey S.
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 16,000 $0.00 --
Grant/Award Common Stock 8,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 16,000 shares (Direct, null); Common Stock — 39,806 shares (Direct, null)
Footnotes (1)
  1. Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan. The RSUs will vest in full on May 27, 2027. The shares subject to the stock option will vest and become exercisable in full on May 27, 2027.
RSU grant 8,000 RSUs Granted to director on May 27, 2026; vest in full May 27, 2027
Stock option grant 16,000 options Right to buy common stock; granted May 27, 2026
Option exercise price $9.10 per share Exercise price for 16,000-share stock option
Shares after RSU grant 39,806 shares Common stock held directly following the transaction
RSU vesting date May 27, 2027 Date when 8,000 RSUs vest in full
Option vesting date May 27, 2027 Date when 16,000 options become fully exercisable
Option expiration May 26, 2036 Expiration date of the 16,000-share stock option
restricted stock units (RSUs) financial
"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
Equity Incentive Plan financial
"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with underlying security title Common Stock."
vesting financial
"The RSUs will vest in full on May 27, 2027."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
exercise price financial
"conversion_or_exercise_price of 9.1000 per share for the stock option."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hatfield Jeffrey S.

(Last)(First)(Middle)
C/O VIR BIOTECHNOLOGY, INC.
1800 OWENS STREET, SUITE 900

(Street)
SAN FRANCISCO CALIFORNIA 94158

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Vir Biotechnology, Inc. [ VIR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/27/2026A(1)8,000(2)A$039,806D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$9.105/27/2026A16,000(3)05/27/202705/26/2036Common Stock16,000$016,000D
Explanation of Responses:
1. Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.
2. The RSUs will vest in full on May 27, 2027.
3. The shares subject to the stock option will vest and become exercisable in full on May 27, 2027.
Remarks:
/s/ Vanina de Verneuil, Attorney-In-Fact05/28/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Vir Biotechnology (VIR) director Jeffrey Hatfield receive?

Jeffrey Hatfield received 8,000 restricted stock units and a stock option for 16,000 shares of Vir Biotechnology common stock. Both awards were granted as compensation under the company’s Equity Incentive Plan, rather than through open-market trading in the company’s shares.

What is the vesting schedule for Jeffrey Hatfield’s new Vir (VIR) RSUs and options?

Both the 8,000 restricted stock units and the stock option covering 16,000 shares will vest in full on May 27, 2027. On that date, the RSUs convert to shares and the option becomes fully exercisable, assuming continued service through vesting.

What is the exercise price and expiration date of Jeffrey Hatfield’s Vir (VIR) stock option?

The stock option granted to Jeffrey Hatfield covers 16,000 shares at an exercise price of $9.10 per share. The option becomes fully exercisable on May 27, 2027 and will expire on May 26, 2036 if not exercised before that date.

How many Vir (VIR) shares does Jeffrey Hatfield own after these equity grants?

After the reported RSU grant, Jeffrey Hatfield directly owns 39,806 shares of Vir Biotechnology common stock. This figure reflects his direct holdings following the non-cash equity compensation award and does not represent any open-market purchase or sale activity.

Are Jeffrey Hatfield’s Vir (VIR) equity grants open-market purchases or sales?

The reported transactions are not open-market trades. They are compensation-related grants: 8,000 restricted stock units and a stock option for 16,000 shares, both awarded at no cash cost to Hatfield under Vir Biotechnology’s Equity Incentive Plan.